CEO and Head of Research
Dr. Karsdal joined Nordic Bioscience in 2001 and rose to CEO in 2010. Dr. Karsdal has led the development of FDA-approved and supported molecular diagnostics and more than 100 commercialized biomarker assays, including both ELISA assays and assays available on high precision automated platforms.
He has extensive experience with clinical trial design in combination with clinical use of biochemical markers. He has conducted extensive research in the field of fibrosis, rheumatology (rheumatoid arthritis and osteoarthritis), diabetes and more. Dr. Karsdal has published more than 700 peer-reviewed articles and has presented at numerous international scientific conferences. Dr. Karsdal oversees several major partnerships as well as over 150 collaborators in Copenhagen.
H-index: 97. i10-index: 560. Citations: 36654 as of August 2024.
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
